EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
Evogene Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$0.37−0.02 (-4.71%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.3
- Dividend yield
- –
Evogene Ltd. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Industrial application [Member] | $2.17M | $2.22M | $1.08M | $72.00K | $40.00K | $33.00K | $26.00K | $106.00K | $134.00K | – | 56.3% | -2.3% |
| Agriculture [Member] | $1.37M | $2.96M | $1.13M | $876.00K | $628.00K | $862.00K | $651.00K | $1.64M | $3.25M | – | 35.7% | -53.5% |
| Unallocated [Member] | $311.00K | $323.00K | $287.00K | $214.00K | $79.00K | $70.00K | $76.00K | – | – | – | 8.1% | -3.7% |
| Human health [Member] | $0 | $80.00K | $487.00K | $513.00K | $183.00K | $75.00K | $0 | – | – | – | 0.0% | -100.0% |
| Evofuel [Member] | – | – | – | – | – | – | – | $106.00K | $134.00K | – | – | – |
| Evogene [Member] | – | – | – | – | – | – | – | $1.64M | $3.25M | $6.54M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Human health [Member] | -$2.65M | -$7.24M | -$10.35M | -$8.88M | -$10.09M | -$4.67M | -$3.22M | -$1.61M | -$637.00K | – | -63.4% |
| Industrial application [Member] | -$3.54M | -$2.41M | -$39.00K | -$220.00K | -$169.00K | -$333.00K | -$419.00K | -$456.00K | -$210.00K | – | +46.8% |
| Unallocated [Member] | -$3.74M | -$3.03M | -$4.77M | -$5.59M | -$8.45M | -$11.13M | -$7.47M | -$10.25M | -$12.75M | – | +23.4% |
| Agriculture [Member] | -$4.10M | -$6.12M | -$7.07M | -$12.26M | -$12.25M | -$8.69M | -$10.06M | -$7.67M | -$8.35M | – | -33.1% |
| Evofuel [Member] | – | – | – | – | – | – | – | -$453.00K | -$313.00K | -$921.00K | – |
| Evogene [Member] | – | – | – | – | – | – | – | -$18.47M | -$21.43M | -$20.17M | – |
| Biomica [Member] | – | – | – | – | – | – | – | -$1.06M | -$204.00K | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Evogene's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.